Navigation Links
Kiwa and Huaxing Set Up Preparatory Team for New Joint-venture Company
Date:4/16/2008

BEIJING and CLAREMONT, Calif., Apr 16 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT), ("the Company" and "Kiwa") announced that on Apr 15, 2008 Mr. Ruijun Li, General Manager of Huaxing Animal Medicine Co., Ltd., met with Mr. Wei Li, Kiwa CEO, and Mr. Lianjun Luo, Kiwa CFO, at Kiwa Beijing headquarters. With the completion of due diligence and the appraisal of the assets, both parties signed a memorandum to establish a new Sino-foreign joint-venture company.

Pursuant to the agreement, both parties appointed members of the Preparatory Team to oversee the establishment of the new joint-venture company including: Team Leader - Mr. Wei Li and Mr. Ruijun Li as Vice Leader. Other members include: Mr. Luo; Mr. Jun Guo, Kiwa CEO Assistant; and Mr. Shubin Gao, Vice General Manager of Huaxing.

In addition, the memorandum stipulates that the parties finalize drafting out, negotiation and subscription of contracts and articles for the new Sino- foreign joint-venture company before May 10; finalize registration by the end of May; and start the preparation of AF-01 post-application tasks. Both parties also discussed the new company management building and the initial steps for setting operational objectives and plans after the joint-venture company is up and running.

ABOUT KIWA BIO-TECH PRODUCTS GROUP CORPORATION

The Company develops, manufactures, distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company has acquired the rights to manufacture and market AF-01 Anti-viral Aerosol Agent for use in preventing (blocking) bird-flu disease in Chinese and international markets. The Company has excellent relations with government authorities in China and has developed several innovative, high margin products, while continuing to grow through internal and external product development. The Company's products are designed to enhance the quality of human life by increasing the value, quality and productivity of crops and decreasing the negative environmental impact of chemicals and other wastes. For more information about the Company, please review documents filed with the SEC (http://www.sec.gov) or visit the Company's website at http://www.kiwabiotech.com .

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward- looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

For more information, please contact:

Kiwa Bio-Tech Products Group Corporation

Yvonne Wang

Tel: +1-626-715-5855

Email: kiwabiotech@gmail.com

Equity Communications

Robert Schechter

Tel: +1-212-499-6809

Email: ir4kiwa@hotmail.com


'/>"/>
SOURCE Kiwa Bio-Tech Products Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kiwa Signs Letter of Intent with Huaxing Animal Medicine
2. DelSite Signs Technology Evaluation Agreement With Global Pharmaceutical Company for GelSite(R) Polymer
3. United BioSource Acquires Leading Publication Planning Software and Services Company
4. Shire to Introduce a New UK Listed Holding Company
5. Larta Institute Partners With Burrill & Company to Present the 14th Annual Life Sciences Venture Forum
6. Cylex Announces Brad L. Stewart as President of the Company
7. Tasty Baking Company Continues Partnership With Alexs Lemonade Stand Foundation To Fight Childhood Cancer
8. HighPoint Solutions Selected by Global Biotechnology Company to Provide Master Data Management Solution
9. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
10. Antibody Engineering Company F-Star Buys Back Royalty Obligations
11. Bioscience Company Chooses Microsoft Dynamics AX to Improve Support for Compliance With Industry Rules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  SeraCare Life ... global in vitro diagnostics manufacturers and clinical ... industry,s first multiplexed Inherited Cancer reference ... by next-generation sequencing (NGS). The Seraseqâ„¢ Inherited ... with input from industry experts to validate ...
(Date:3/23/2017)... MENLO PARK, Calif., March 23, 2017  BioPharmX ... developing products for the dermatology market, today reported ... Jan. 31, 2017, and will provide an update ... from the year. "We are pleased ... productive year for BioPharmX," said President Anja Krammer. ...
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
(Date:3/23/2017)... New York , March 23, 2017 ... blood plasma products and derivatives market is fragmented due to the presence ... players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete ... leader, these three companies, collectively, held more than 76% of this ... ...
Breaking Biology Technology:
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/9/2017)... , Feb. 9, 2017 The biomass ... analysis of the biomass boiler market globally in terms ... of biomass boilers. The market for biomass boilers has ... type, end-user, application, and country/region. The market based on ... & forest residues, biogas & energy crops, urban residues, ...
Breaking Biology News(10 mins):